MTSL Issue 968

MTSL Issue 968 (dated 01/20/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #INCY #incyte #IONS #ionis #MDGL #madrigal #MYOV #myovant #NKTR #nektar #PGEN #precigen

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on January 23, 2022January 22, 2022 by conniebioinvest

Acadia (ACAD) — ACAD Narrows Resubmitted sNDA For Pimavanserin to Alzheimer’s Disease Psychosis From Dementia-related Psychosis

Acadia (ACAD) – Yesterday after the close ACAD announced that it plans to resubmit its supplemental New Drug Application (sNDA) to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with dementia. Read more…

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on December 21, 2021April 11, 2022 by conniebioinvest

The MoneyShow Live Conference (December 7, 2021)

Please join BioInvest FREE at The MoneyShow live streaming event from December 7-9 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country.

Posted on December 2, 2021 by conniebioinvest

Precigen (PGEN) — R&D Update Highlights Depth & Breadth of Novel Pipeline – BUY

BIOINVEST BREAKING NEWS – Precigen held a virtual R&D presentation yesterday, updating data on five clinical trials from the novel Ultra-CAR-T and AdenoVerse platforms. The company has delivered objective responses in late-stage, refractory cancer patients (AML, ovarian, HPV-positive tumors) utilizing their Ultra-CAR-T system plus which offer the fastest (overnight vs. 4-6 weeks) low-cost CAR-T therapies around. (…more)

Posted on November 5, 2021November 10, 2021 by conniebioinvest

MTSL Issue 967

MTSL Issue 967 (dated 01/06/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #MDGL #madrigal #MYOV #myovant #PCRX #pacira #PLXP #plxpharma #SGMO #sangamo

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on January 9, 2022October 7, 2022 by conniebioinvest

Esperion (ESPR) — ESPR Raises Cash To Get To CLEAR Outcomes Trial Data in Q12023

(ESPR) BioInvest News — ESPR Raises Cash To Get To CLEAR Outcomes Trial Data in Q12023, Lowering our BUY and our TARGET PRICE. ESPR shares were off 40% after they announced the closing of a $208.8 million of common stock and warrants. (More)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on December 8, 2021February 17, 2022 by conniebioinvest

MTSL Issue 964

MTSL Issue 964 (dated 11/11/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ALKS #alkermes #IONS #ionis #MDGL #madrigal #NKTR #nektar #PCRX #pacira #PLXP #plxpharma #PGEN #precigen #SGMO #sangamo

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 14, 2021December 3, 2021 by conniebioinvest

Sangamo (SGMO) — SGMO’s PhaseI/II Fabry Disease Data Looks Great

BioInvest News – SGMO’s PhaseI/II Fabry Disease Data Looks Great – In it’s quarterly update, SGMO delivered news across multiple clinical programs today with the stock reacting positively to the excellent Fabry disease data. (…more)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 4, 2021November 10, 2021 by conniebioinvest

MTSL Issue 966

MTSL Issue 966 (dated 12/23/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #CLDX #celldex #ESPR #esperion #NKTR #nektar #PCRX #pacira #PGEN #precigen #SGMO #sangamo #VXRT #vaxart

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on December 26, 2021December 24, 2021 by conniebioinvest

MTSL Issue 965

MTSL Issue 965 (dated 12/02/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #biomarin #NKTR #nektar #VXRT #vaxart

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on December 5, 2021December 3, 2021 by conniebioinvest

Alkermes (ALKS) — ALKS Blindsided by JNJ Early Termination of Invega Sustenna & Invega Trinza Know-How Royalties

Alkermes (ALKS) — ALKS was blindsided by JNJ after the close yesterday received notices of partial early termination for two license agreements with Janssen Pharmaceutica N.V., a subsidiary of JNJ. These license agreements are for Alkermes’ nanoparticulate formulation technology, known as NanoCrystal® technology. (…more)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 9, 2021November 10, 2021 by conniebioinvest

MTSL Issue 963

MTSL Issue 963 (dated 10/28/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #IONS #ionis #MYOV #myovant #PGEN #precigen #VXRT #vaxart

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on October 31, 2021October 29, 2021 by conniebioinvest